NATF Northeast Anticoagulation Stewardship Council Inaugural In-Person Meeting, October 25, 2024
Mass General Headquarters - Boston, MA - October 25, 2024
Claiming Credit
Thank you for participating in this program. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to complete evaluation and claim your credit on the following page.
Target Audience
This continuing education activity is developed for pharmacists and nurses.
Learning Objectives
At the conclusion of this activity, participants will be better able to:
- Describe the evolving landscape of anticoagulation management, including the latest developments in Factor XI/XIa inhibitors, DOAC management, and reversal strategies
- Identify opportunities for inpatient antithrombotic stewardship initiatives and best practices to optimize resource utilization
- Examine how technology can be leveraged for improved patient monitoring and patient engagement
- Apply clinical and operational knowledge to navigate complex patient cases and healthcare delivery scenarios in anticoagulation therapy
Program Agenda
9:00 – 9:30 am Welcoming Remarks
9:30 – 10:00 am Keynote Address
10:00 - 11:00 am Session 1: Latest in Inpatient Stewardship Initiatives (Reversal, formulary substitutions, lab initiatives, TNK)
Katie Dane, PharmD, Johns Hopkins University
and
Session 2: Anticoagulation Clinic Systems Integration: Lessons from a Large Hospital System
Anne Rose, PharmD, University of Wisconsin
11:00 – 11:15 am Networking Break
11:15 –12:00 pm Session 3: Leveraging Technology for Improved Monitoring and Patient Engagement; Bracken Babula, MD, Thomas Jefferson University Hospital
12:00 – 1:15 pm Networking Lunch
1:15 - 2:00 pm Session 4: Navigating Complex Patient Scenarios Panel Discussion
Jean Connors, MD, John Fanikos, RPh, MBA, Katie Dane, PharmD, Anne Rose, PharmD, Bracken Babula, MD
2:00 - 2:30 pm Break
2:30 - 3:30 pm Roundtable Discussions: Discuss specific areas of anticoagulation stewardship formulary choice,
medication selection/utilization and barriers to care.
Jean Connors, MD, John Fanikos, RPh, MBA, Katie Dane, PharmD, Anne Rose, PharmD, Bracken Babula, MD
3:30 - 4:00 pm Closing Remarks and Adjournment
Tara Lech, PharmD, Katelyn Sylvester, PharmD
Boston University Chobanian & Avedisian School of Medicine Disclosure Policy
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.
Speakers Disclosures
Drs. Bracken, Dane and Rose have no relevant financial relationships to disclose.
Dr. Connors is a consultant for Abbott, Alnylam Pharmaceuticals, Anthos, Bristol-Meyers Squibb, and Pfizer. She is also a speaker for Sanofi. She is on the scientific advisory boards for consultant for Abbott, Anthos, Bristol-Meyers Squibb, Pfizer and Sanofi.
Dr. Fanikos is a consultant for Anthos Therapuetics, Astra-Zeneca, Pfizer and TG Therapeutics. He is also a speaker for Astra Zeneca.
Off-Label Discussion
Will be included in Dr. Dane's presentation: Coagulation Factor VIIA (Recombinant)-jncw for injection (SevenFACT®) and Coagulation factor VIIa Recombinant (NovoSeven®) use for refractory bleeding in the setting of surgery or trauma and acquired hemophilia; Anti-inhibitor Coagulant Complex (FEIBA®) for acquired hemophilia bleeding management; Antithrombin III (Human) Thrombate-III® use for heparin resistance; continuous infusion administration of Antihemophilic factor (Recombinant) (Advate®); Antihemophilic factor/von Willebrand factor complex (human) (Alphanate®); Coagulation Factor IX (recombinant) (BeneFIX®); Antihemophilic Factor/von Willebrand Factor Complex (Human) (Humate-P®).
Planning Committee and Disclosures
Dr. Hill, member of the planning committee and pharmacy accreditation reviewer, has no relevant financial relationships to disclose.
Dr. Lech, Co-Course Director, has no relevant financial relationships to disclose.
Dr. Sargent, member of the planning committee and pharmacy accreditation reviewer, has no relevant financial relationships to disclose.
Dr. Sylvester, Co-Course Director, has no relevant financial relationships to disclose.
Ms. Whalen, Boston University Center for Continuing Education's nursing accreditation reviewer, has no relevant financial relationships to disclose.
Accreditor Disclosures
The following planning committee members from Boston University Chobanian & Avedisian School of Medicine’s Center for Continuing Education have no relevant financial relationships to disclose: Dr. Daniel Alford, Boston University’s CME Course Director and Assistant Dean and Michael Burk, BS, Operations Manager.
Joint Accreditation
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Vasculearn Network. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Contact Hours: 4.5, all of which are eligible for pharmacology credits.
Pharmacist Contact Hours
This activity is approved for 4.5 CPE credit(s) under the ACPE universal activity number JA0000185-9999-24-034-L04-P. The activity is available for credit claiming through December 23, 2024.
Available Credit
- 4.50 ACPE Pharmacy
- 4.50 ANCC
- 4.50 ANCC Pharmacology
- 4.50 Participation